首页 > 市场调查报告书 > 製药

市场调查报告书

商品编码

1085486

脊索瘤治疗药的全球市场:各类药物，各治疗类型，各终端用户，各地区-规模，占有率，展望，机会分析(2022年～2028年)

Chordoma Disease Therapeutics Market, by Drug Class, by Treatment Type, by End User, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

出版日期: 2022年05月06日 | 出版商:

Coherent Market Insights | 英文 201 Pages | 商品交期: 2-3个工作天内

价格

简介目录

由于脊索瘤的治疗研究开发活动活性化，牵引在预测期间内的脊索瘤治疗药市场成长。

本报告提供全球脊索瘤治疗药市场的相关调查，市场展望，市场动态，市场分析，竞争情形等全面性资讯。

热图分析
市场占有率分析
- GlaxoSmithKline Plc
- 设备组合
- Bavarian Nordic
- 设备组合
- Boehringer Ingelheim International GmbH
- 设备组合
- Pfizer, Inc.
- 设备组合
- Merck &Co., Inc.
- 设备组合
- Sanofi SA
- 设备组合
- Astellas Pharma Inc.
- 设备组合
- AstraZeneca plc
- 设备组合
- Amgen, Inc.
- 设备组合
- Bristol-Myers Squibb and Company
- 设备组合
- Novartis International AG
- 设备组合
- Bayer AG
- 设备组合
- Dr. Reddy's Laboratories Ltd.
- 设备组合
- Mylan NV
- 设备组合
分析师的见解

第6章 Section

简介目录

Product Code: CMI3979

Chordoma is a rare cancer along with many treatment limitations. The tumor grows slowly in the bones of skull and spine when an individual is suffering from chordoma. Around half of all chordomas occur at the sacrum (base of the spine), approximately one third occur in the occiput (base of the skull), while rest of the chordomas occur in the cervical (neck), thoracic (upper back) or lumbar (lower back) vertebrae of the spine. A chordoma growth in the spine region may cause weakness, pain or numbness in the back, legs or arms. An occipital chordoma (chordoma at the base of skull) may lead to diplopia (double vision) and headaches while coccygeal chordoma (chordoma occurring in the tailbone) may result in a large lump, which may cause problems with bladder or bowel function.

Although chordoma is a rare type of cancer, increasing research and development activities for its treatment is likely to drive growth of the chordoma disease therapeutics market over the forecast period.

Market Dynamics

The increasing number of research and development activities by key players operating in the market, in order to develop advanced treatment for chordoma, is expected to propel the market growth over the forecast period. For instance, in June 2018, Boehringer Ingelheim, a pharmaceutical company, initiated phase 2 clinical trial in collaboration with the Chordoma Foundation, a non-profit organization. The purpose of the trial was to evaluate the safety and efficacy of Afatinib, a tyrosine kinase inhibitor, as first line or later line treatment in advanced chordoma.

Key features of the study:

This report provides in-depth analysis of the global chordoma disease therapeutics market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global chordoma disease therapeutics market based on the following parameters - company overview, financial performance, Drugs portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include GlaxoSmithKline Plc, Bavarian Nordic A/S, Boehringer Ingelheim International GmbH, Pfizer, Inc., Merck & Co., Inc., Sanofi SA, Astellas Pharma Inc., AstraZeneca plc, Amgen, Inc., Bristol-Myers Squibb and Company, Novartis International AG, Bayer AG, Dr. Reddy's Laboratories Ltd., and Mylan N.V.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future drug launches, drug class up-gradation, market expansion, and marketing tactics
The global chordoma disease therapeutics market report caters to various stakeholders in this industry including investors, suppliers, drugs manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chordoma disease therapeutics market

Detailed Segmentation:

Global Chordoma Disease Therapeutics Market, By Drug Class:
- Antimetabolites
- Anthracycline
- VEGFR Inhibitors
- EGFR Inhibitor
- Others
Global Chordoma Disease Therapeutics Market, By Treatment Type:
- Chemotherapy
- Targeted Therapy
- Radiation Therapy
- Others
Global Chordoma Disease Therapeutics Market, By End User:
- Hospitals
- Clinics
- Oncology Centers
- Others
Global Chordoma Disease Therapeutics Market, By Region:
- North America
  - By Drug Class:
  - Antimetabolites
  - Anthracycline
  - VEGFR Inhibitors
  - EGFR Inhibitor
  - Others
  - By Treatment Type
  - Chemotherapy
  - Targeted Therapy
  - Radiation Therapy
  - Others
  - By End User:
  - Hospitals
  - Clinics
  - Oncology Centers
  - Others
  - By Country:
  - U.S.
  - Canada
- Latin America
  - By Drug Class:
  - Antimetabolites
  - Anthracycline
  - VEGFR Inhibitors
  - EGFR Inhibitor
  - Others
  - By Treatment Type
  - Chemotherapy
  - Targeted Therapy
  - Radiation Therapy
  - Others
  - By End User:
  - Hospitals
  - Clinics
  - Oncology Centers
  - Others
  - By Country:
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
- Europe
  - By Drug Class:
  - Antimetabolites
  - Anthracycline
  - VEGFR Inhibitors
  - EGFR Inhibitor
  - Others
  - By Treatment Type
  - Chemotherapy
  - Targeted Therapy
  - Radiation Therapy
  - Others
  - By End User:
  - Hospitals
  - Clinics
  - Oncology Centers
  - Others
  - By Country:
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
- Asia Pacific
  - By Drug Class:
  - Antimetabolites
  - Anthracycline
  - VEGFR Inhibitors
  - EGFR Inhibitor
  - Others
  - By Treatment Type
  - Chemotherapy
  - Targeted Therapy
  - Radiation Therapy
  - Others
  - By End User:
  - Hospitals
  - Clinics
  - Oncology Centers
  - Others
  - By Country:
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
- Middle East
  - By Drug Class:
  - Antimetabolites
  - Anthracycline
  - VEGFR Inhibitors
  - EGFR Inhibitor
  - Others
  - By Treatment Type
  - Chemotherapy
  - Targeted Therapy
  - Radiation Therapy
  - Others
  - By End User:
  - Hospitals
  - Clinics
  - Oncology Centers
  - Others
  - By Country:
  - GCC
  - Israel
  - Rest of Middle East
- Africa
  - By Drug Class:
  - Antimetabolites
  - Anthracycline
  - VEGFR Inhibitors
  - EGFR Inhibitor
  - Others
  - By Treatment Type
  - Chemotherapy
  - Targeted Therapy
  - Radiation Therapy
  - Others
  - By End User:
  - Hospitals
  - Clinics
  - Oncology Centers
  - Others
  - By Country/Region:
  - South Africa
  - Central Africa
  - North Africa
Company Profiles
- GlaxoSmithKline Plc *
  - Company Overview
  - Material Portfolio
  - Financial Performance
  - Key Highlights
  - Market Strategies
- Bavarian Nordic A/S
- Boehringer Ingelheim International GmbH
- Pfizer, Inc.
- Merck & Co., Inc.
- Sanofi SA
- Astellas Pharma Inc.
- AstraZeneca plc
- Amgen, Inc.
- Bristol-Myers Squibb and Company
- Novartis International AG
- Bayer AG
- Dr. Reddy's Laboratories Ltd.
- Mylan N.V.

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Treatment Type
- Market Snippet, By End User
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Key Developments
PEST Analysis

4. Global Chordoma Disease Therapeutics Market - Impact of Coronavirus (Covid-19) Pandemic

Impact assessment
Pre COVID-19 Market Scenario
Post COVID-19 Market Scenario
Government measures to combat COVID-19

1. Global Chordoma Disease Therapeutics Market, By Drug Class, 2017 - 2028, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Antimetabolites
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Anthracycline
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
VEGFR Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
EGFR Inhibitor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

2. Global Chordoma Disease Therapeutics Market, By Treatment Type, 2017 - 2028, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Chemotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Targeted Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Radiation Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

3. Global Chordoma Disease Therapeutics Market, By End User, 2017 - 2028, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Oncology Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

4. Global Chordoma Disease Therapeutics Market, By Region, 2017 - 2028, (US$ Mn)

Introduction
- Market Share Analysis, By Region, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, For Regions, 2017 - 2028
North America
- Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Treatment Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By End User, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- U.S.
- Canada
Latin America
- Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Treatment Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By End User, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Europe
- Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Treatment Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By End User, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific
- Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Treatment Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By End User, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Treatment Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By End User, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
Africa
- Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Treatment Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By End User, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country/Region, 2017 - 2028, (US$ Mn)
- South Africa
- Central Africa
- North Africa

5. Competitive Landscape

Heat Map Analysis
Market Share Analysis
- GlaxoSmithKline Plc
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Bavarian Nordic
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Boehringer Ingelheim International GmbH
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Pfizer, Inc.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Merck & Co., Inc.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Sanofi SA
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Astellas Pharma Inc.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- AstraZeneca plc
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Amgen, Inc.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Bristol-Myers Squibb and Company
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Novartis International AG
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Bayer AG
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Dr. Reddy's Laboratories Ltd.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Mylan N.V.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Analyst Views

6. Section

References
Research Methodology
About us and Sales Contact

02-2729-4219

+886-2-2729-4219

License/价格

FAQ

脊索瘤治疗药的全球市场:各类药物，各治疗类型，各终端用户，各地区-规模，占有率，展望，机会分析(2022年～2028年)

Chordoma Disease Therapeutics Market, by Drug Class, by Treatment Type, by End User, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

目录

第1章调查目的、前提条件

第2章市场展望

第3章市场动态，法规，及趋势分析

第4章全球脊索瘤治疗药市场 - 冠状病毒(COVID-19)大流行的影响

第1章全球脊索瘤治疗药市场:各类药物(100万美元)(2021年～2028年)

第2章全球脊索瘤治疗药市场:各治疗类型(100万美元)(2021年～2028年)

第3章全球脊索瘤治疗药市场:各终端用户(100万美元)(2021年～2028年)

第4章全球脊索瘤治疗药市场:各地区(100万美元)(2021年～2028年)

第5章竞争情形

第6章 Section

Market Dynamics

Key features of the study:

Detailed Segmentation:

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Chordoma Disease Therapeutics Market - Impact of Coronavirus (Covid-19) Pandemic

1. Global Chordoma Disease Therapeutics Market, By Drug Class, 2017 - 2028, (US$ Mn)

2. Global Chordoma Disease Therapeutics Market, By Treatment Type, 2017 - 2028, (US$ Mn)

3. Global Chordoma Disease Therapeutics Market, By End User, 2017 - 2028, (US$ Mn)

4. Global Chordoma Disease Therapeutics Market, By Region, 2017 - 2028, (US$ Mn)

5. Competitive Landscape

6. Section

脊索瘤治疗药的全球市场:各类药物，各治疗类型，各终端用户，各地区-规模，占有率，展望，机会分析(2022年～2028年)

Chordoma Disease Therapeutics Market, by Drug Class, by Treatment Type, by End User, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

目录

第1章 调查目的、前提条件

第2章 市场展望

第3章 市场动态，法规，及趋势分析

第4章 全球脊索瘤治疗药市场 - 冠状病毒(COVID-19)大流行的影响

第1章 全球脊索瘤治疗药市场:各类药物(100万美元)(2021年～2028年)

第2章 全球脊索瘤治疗药市场:各治疗类型(100万美元)(2021年～2028年)

第3章 全球脊索瘤治疗药市场:各终端用户(100万美元)(2021年～2028年)

第4章 全球脊索瘤治疗药市场:各地区(100万美元)(2021年～2028年)

第5章 竞争情形

第6章 Section

Market Dynamics

Key features of the study:

Detailed Segmentation:

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Chordoma Disease Therapeutics Market - Impact of Coronavirus (Covid-19) Pandemic

1. Global Chordoma Disease Therapeutics Market, By Drug Class, 2017 - 2028, (US$ Mn)

2. Global Chordoma Disease Therapeutics Market, By Treatment Type, 2017 - 2028, (US$ Mn)

3. Global Chordoma Disease Therapeutics Market, By End User, 2017 - 2028, (US$ Mn)

4. Global Chordoma Disease Therapeutics Market, By Region, 2017 - 2028, (US$ Mn)

5. Competitive Landscape

6. Section

第1章调查目的、前提条件

第2章市场展望

第3章市场动态，法规，及趋势分析

第4章全球脊索瘤治疗药市场 - 冠状病毒(COVID-19)大流行的影响

第1章全球脊索瘤治疗药市场:各类药物(100万美元)(2021年～2028年)

第2章全球脊索瘤治疗药市场:各治疗类型(100万美元)(2021年～2028年)

第3章全球脊索瘤治疗药市场:各终端用户(100万美元)(2021年～2028年)

第4章全球脊索瘤治疗药市场:各地区(100万美元)(2021年～2028年)

第5章竞争情形